
Venture programme of Research Corporation Technologies investing in early-stage biomedical and life science companies

Life-science venture and public equity investor building biopharma, drug delivery and instrument companies

Life-science companies, from academic discoveries to later-stage biotech, are the focus of 5AM Ventures, a firm founded in 2002 that builds companies as well as funding them. Its areas are biopharmaceuticals, drug delivery and life-science instruments, and it describes its aim as building next-generation companies that can address important healthcare needs.
The venture strategy mainly invests in private therapeutic companies at an early stage, with an emphasis on Series A financings. The opportunities strategy invests in small and mid-cap public biotech companies and in later-stage private life-science companies. Together the two strategies give the firm exposure to companies at very different points in their development.
The 4:59 initiative is the firm's hands-on internal effort to discover, incubate and fund breakthrough science. Working with academics and entrepreneurs, 5AM often acts as an extension of their operating team, helping them establish proof-of-concept data that can support a Series A financing.
The firm says patients enrolled in trials run by its portfolio companies number more than ninety thousand, across more than 450 sites. Its recent news covers clinical results, financings and public offerings among portfolio companies. Examples include CAMP4, which is preparing a first-in-human trial for a rare disease linked to SYNGAP1 after receiving clearance in Australia, and Dianthus, IDEAYA, Vor Bio and Rezera, which the firm lists among companies it has supported.
5AM Ventures is a life-science investment firm founded in 2002. It concentrates on biopharmaceuticals, drug delivery technologies and life-science instruments, and it also helps to create companies as well as fund them.
Academics and entrepreneurs with early scientific ideas, and biotech companies in clinical development.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
5AM Ventures is ranked on 3 TrustList rankings: #10 on 1, #11 on 1 and #18 on 1.
Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. 5AM Ventures has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.
It is one of 17 here listing science.
Of the top 65 here, 22 also cover healthtech and 17 also cover science; 14 also work in Boston and 13 also work in San Francisco.
Ahead of BVCF Management.
It is one of 11 here listing biotech.
Of the top 69 here, 11 also cover biotech and 10 also cover seed stage; 21 also work in London and 18 also work in New York City.
Behind Flagship Pioneering, ahead of Bain Capital Ventures.
It is one of 4 here listing biotech and science.
Of the top 53 here, 10 also cover partners and 9 also cover artificial intelligence; 16 also work in Silicon Valley and 5 also work in Hong Kong.
Ahead of CFO Rick, Inc..
As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about 5AM Ventures.
Similar listings buyers compare against this one.

Venture programme of Research Corporation Technologies investing in early-stage biomedical and life science companies

Boutique M&A advisory firm for sell-side and buy-side deals in business technology, finance and industrials

A life sciences venture fund investing in biotechnology and biopharma companies across multiple stages

UK build-to-rent housing developer and manager delivering new family rental homes

Former life sciences venture capital fund in Germany and Switzerland, now in liquidation

Growth fund backed by tech founders, investing in African technology companies as they scale

Estonian investment company backing fast-growing digital businesses in crypto, software and SaaS

A venture capital fund investing in early-stage artificial intelligence companies since 2017
Everything here links back to the same verified catalogue. Pick your next stop.